Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4230426 | 0.94 | CXCR4 (0.44) | CXCR4KMT2AMEN1MAPK1POLB | |
| SCHEMBL4230314 | 0.90 | CXCR4 (0.43) | CXCR4KMT2AMEN1MAPK1POLB | |
| SCHEMBL2692946 | 0.89 | CXCR4 (0.45) | CXCR4KMT2AMEN1MAPK1POLB | |
| SCHEMBL4233793 | 0.88 | CXCR4 (0.45) | CXCR4KMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL4230860 | 0.88 | CXCR4 (0.40) | CXCR4KMT2AALDH1A1CASP1KDM4E | |
| SCHEMBL4225603 | 0.88 | CXCR4 (0.42) | CXCR4KMT2AMEN1MAPK1POLB | |
| SCHEMBL4237781 | 0.87 | CXCR4 (0.44) | CXCR4KMT2AMEN1MAPK1POLB | |
| SCHEMBL13778402 | 0.87 | CXCR4 (0.44) | CXCR4KMT2AMEN1MAPK1POLB | |
| SCHEMBL4235188 | 0.86 | CXCR4 (0.44) | CXCR4KMT2AMEN1MAPK1CYP3A4 | |
| SCHEMBL4225549 | 0.86 | CXCR4 (0.44) | CXCR4KMT2AMEN1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2042503-B1 | COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2013-01-30 | — | — | EP | disclosed |
| US-20090192182-A1 | COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF | ONO PHARMACEUTICAL CO.,LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| EP-2042503-A1 | COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192182-A1 | COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF | CXCR4, CXCR3, CXCL12 | CXCR4 1/4885KMT2A 4124/4885MEN1 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.